Rubella virus vaccine

Identification

Summary

Rubella virus vaccine is a vaccine used to prevent Rubella.

Brand Names

M-M-R II, Proquad

Generic Name

Rubella virus vaccine

DrugBank Accession Number

DB10317

Background

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Vaccines
Attenuated

Synonyms

• Rubella virus (vaccine strain RA27/3) live antigen
• Rubella virus live antigen, A
• Rubella virus strain Wistar RA 27/3 live (attenuated) antigen
• Rubella virus strain Wistar RA 27/3 live antigen
• Rubella virus vaccine live (Wistar RA 27-3 strain)
• Rubella virus vaccine live attenuated (Wistar RA27/3 strain)
• Rubella virus vaccine,live
• Rubella, live attenuated
• Rubivirus rubella virus Wistar RA 27/3 whole

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Rubella

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
Abatacept	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
Acyclovir	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
Adalimumab	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
Adefovir dipivoxil	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil.
Aldesleukin	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
Alefacept	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
Alemtuzumab	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
Altretamine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine.
Amantadine	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Meruvax II

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Rubella Virus Vacc Live Att Freez Dried Inj	Powder, for solution	1000 unit / vial	Subcutaneous	Iaf Biovac Inc.	1991-12-31	1997-08-20
Rubella Virus Vaccine Live Dried Attenuated	Powder, for solution	1000 unit / 0.5 mL	Subcutaneous	Aventis Pasteur Limited	1983-12-31	2000-04-07

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	A-S Medication Solutions	1971-04-21	Not applicable
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Physicians Total Care, Inc.	1996-08-07	2012-06-30
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Merck Sharp & Dohme Corp.	1971-04-21	Not applicable
M-M-R II	Rubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)	Powder, for solution	Subcutaneous	Merck Ltd.	1979-12-31	Not applicable
M-M-R II VACCINE	Rubella virus vaccine (1000 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL)	Injection, powder, for solution	Subcutaneous	MSD PHARMA (SINGAPORE) PTE. LTD.	1988-06-24	Not applicable
M-M-rvaxpro	Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)			Merck Sharp & Dohme B.V.	2021-02-10	Not applicable
M-M-rvaxpro	Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)			Merck Sharp & Dohme B.V.	2021-02-10	Not applicable
M-M-rvaxpro	Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)	Injection, powder, for suspension	Intramuscular; Subcutaneous	Merck Sharp & Dohme B.V.	2021-02-10	Not applicable
M-M-rvaxpro	Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)	Injection, powder, for suspension	Intramuscular; Subcutaneous	Merck Sharp & Dohme B.V.	2021-02-10	Not applicable
M-M-rvaxpro	Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)			Merck Sharp & Dohme B.V.	2021-02-10	Not applicable

Categories

ATC Codes

J07BD53 — Measles, combinations with rubella, live attenuated

• J07BD — Measles vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J07BD54 — Measles, combinations with mumps, rubella and varicella, live attenuated

• J07BD — Measles vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J07BD52 — Measles, combinations with mumps and rubella, live attenuated

• J07BD — Measles vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J07BJ01 — Rubella, live attenuated

• J07BJ — Rubella vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J07BJ51 — Rubella, combinations with mumps, live attenuated

• J07BJ — Rubella vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J07BD51 — Measles, combinations with mumps, live attenuated

• J07BD — Measles vaccines
• J07B — VIRAL VACCINES
• J07 — VACCINES
• J — ANTIINFECTIVES FOR SYSTEMIC USE

Drug Categories

• Actively Acquired Immunity
• Antiinfectives for Systemic Use
• Live Attenuated Rubella Virus Vaccine
• Live vaccines
• Measles vaccines
• Rubella Vaccines
• Vaccines
• Viral Vaccines

Classification

Not classified

Affected organisms

Not Available

Chemical Identifiers

UNII

52202H034Z

CAS number

Not Available

References

General References

1. TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]

External Links

PubChem Substance

347910496

RxNav

9486

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Children / Death / Measles Vaccination / Morbidity / Non-specific/Heterologous Effects of Vaccines / Oral Polio Vaccine	1
4	Active Not Recruiting	Prevention	Hepatitis A / Measles / Varicella	1
4	Completed	Not Available	Rheumatoid Arthritis, Juvenile	1
4	Completed	Diagnostic	Diphtheria / Measles / Pertussis / Tetanus	1
4	Completed	Prevention	Adverse Event Following Immunization / Measles / Mumps / Rubella	1
4	Completed	Prevention	BCG Infection / Immune Responses / Vaccine Reaction	1
4	Completed	Prevention	Chickenpox / Hepatitis A / Measles / Mumps / Rubella	1
4	Completed	Prevention	Death / Vaccines	1
4	Completed	Prevention	Hepatitis A Virus	1
4	Completed	Prevention	Hepatitis A / Measles / Mumps / Rubella	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Subcutaneous
Injection, powder, lyophilized, for suspension	Subcutaneous
Injection, powder, for solution	Subcutaneous	1000 CCID50/0.5mL
Injection, powder, for suspension	Intramuscular; Subcutaneous
Injection, powder, lyophilized, for solution	Intramuscular; Subcutaneous
Liquid; powder, for solution	Subcutaneous
Injection, powder, for solution	Subcutaneous
Kit; powder, for solution	Intramuscular; Subcutaneous
Injection, solution	Intramuscular; Subcutaneous
Injection, powder, for solution	Intramuscular; Subcutaneous
Injection, powder, for solution	Intramuscular; Subcutaneous	1000 TCID50/0.5ml
Injection
Injection, powder, lyophilized, for solution	Intramuscular; Subcutaneous	1000 CCID50
Powder, for solution	Intramuscular; Subcutaneous
Powder, for solution	Subcutaneous
Injection, powder, lyophilized, for suspension	Intramuscular; Subcutaneous
Injection, powder, lyophilized, for solution	Subcutaneous	3 log10 tcid50/0.5mL
Injection	Subcutaneous
Powder, for solution	Subcutaneous	1000 unit / vial
Powder, for solution	Subcutaneous	1000 unit / 0.5 mL
Injection	Subcutaneous
Injection, powder, lyophilized, for suspension	Subcutaneous
Solution
Injection, powder, lyophilized, for suspension
Powder

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at December 01, 2015 20:03 / Updated at May 28, 2022 06:24